Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin dose (300 IU/kg vs. 600 IU/kg) in coronary artery bypass grafting
2012-000449-11Phase 4Terminated
- Sponsor
- Eero Pesonen
- Start
- Feb 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of heparin in coronary arteriosclerosis (2 arms), sponsored by Eero Pesonen. Primary endpoint: Perioperative bleeding. Started Feb 2012; status: terminated.
02
Drugs
heparin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2012-000449-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000449-11.